CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Pandion Therapeutics, Inc. (“Pandion”), and Astellas Pharma Inc. (TSE: 4503, “Astellas”) announced today the signing of a License and Collaboration Agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of … Continue reading Pandion and Astellas Announce Collaboration to Deliver Pancreas-Targeted Immunomodulators